Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 4,238 shares at $30.10 ($128K) on 2023-02-13, disclosed to the SEC on 2023-02-15.
Open-market sale of $128k DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.10 | 2,119 | $64K | 50.0% |
| 2 | $30.10 | 2,119 | $64K | 50.0% |
| Total | $30.10 avg | 4,238 | $128K | 100% |
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |